ASCERTAIN

🎄✨ #Christmas greetings from the #ASCERTAIN team! ✨🎄 As the year draws to a close, we would like to send our best wishes to all of you. 2024 has been an exciting year for ASCERTAIN as we continue to work together to improve the affordability and accessibility of innovative health technologies across Europe. From workshops and publications to videos and events, we have made great strides - thanks to the collaboration and dedication of our incredible team. 🌟 Here's to an even more impactful 2025! We look forward to sharing more insights with you, engaging new partners and driving meaningful change in healthcare. We wish you all a Merry Christmas and a happy, healthy #NewYear! 🥂

🔬 Exploring Sustainable Healthcare: Renaud Heine’s PhD Thesis Defense on Access to Innovative Medicines 💊 Over the past decade, life expectancy has increased alongside rising health expenditures, driven largely by an aging population and groundbreaking innovations in cancer treatments. Efficient resource allocation remains critical as we navigate the growing costs of healthcare. Renaud Heine’s thesis provides a comprehensive analysis of the challenges and opportunities in ensuring access to innovative therapies, particularly in cancer care. His research is divided into four key sections, each shedding light on different aspects of healthcare economics: - #Access to Innovative Cancer Medicines - Economic Impact of #CAR-T Therapies - #Pricing Models for Rare Diseases and Immuno-Oncology Drugs - Managed Entry Agreements (#MEAs) – with a focus on pembrolizumab across several indications. Heine’s work underscores the delicate balance between advancing medical innovation and maintaining sustainable healthcare expenditure. The potential of cost-based pricing and MEAs presents promising solutions to improve the affordability and accessibility of life-saving treatments, ensuring they reach the patients who need them most. 💡 This research is essential reading for policymakers, healthcare professionals, and anyone interested in the future of #equitable healthcare access. Let’s continue to advocate for innovative solutions that make groundbreaking therapies both #affordable and #accessible to patients worldwide. Special thanks to all co-authors and to Birgit Koch, Henk Verheul, marcel canoy, Frank Leebeek, Pr. Isabelle Durand-Zaleski, Lonneke Timmers, and Ken Redekop for their valuable contributions to this journey. Erasmus Universiteit Rotterdam, Erasmus School of Health Policy & Management (ESHPM), ErasmusMC, ASCERTAIN. #HealthcareEconomics #InnovationInMedicine #CancerResearch #PharmaceuticalPricing #HealthPolicy #SustainableHealthcare #PhDResearch #AccessToMedicine #CostEffectiveness  

This year, iMTA and Erasmus School of Health Policy & Management (ESHPM) are well represented at the ISPOR 2024 conference in Barcelona, Spain, on 17-20 November 2024. We have, a.o. 21 poster presentations on topics like HTA of AI application, Price determination and pricing policies concerning potentially innovative health technologies and Social influence on patient choices. View all our contributions and/or find us at the ISPOR booth 929 at the Barcelona International Convention Center. Read all our contributions here: https://lnkd.in/e3kCd2Uk

An exciting experience at ISPOR in Barcelona! I’m thrilled to share that I had the opportunity to bring my poster, which is titled “Using Structured Expert Elicitation in Cost-Effectiveness Analysis: An Exploratory Case Evaluating Selpercatinib for Thyroid Cancer in Norway”, to the ISPOR conference. This research was the focus of my master’s thesis, and I collaborated closely with Carin Uyl-de Groot, Eline Aas, Yansi Wu, Emily Burger and Fredrik Holmboe to develop and present the findings. In addition to presenting the work, I attended informative courses on structured expert elicitation, which allowed me to gain further insights on this interesting topic. The conference also provided a great opportunity to connect with other professionals and expand my network. Looking forward to bringing these insights into practice!

Read Myeloma Patients Europe (MPE) Year in Review 😊

Do you have novel clinical or research data to share? #EHA2025 is your opportunity to showcase your work. 📅 Registration and abstract submission open on January 1, 2025. 👉 Learn more here: https://lnkd.in/e6nk8apc

As we close in on 2025, we're already looking forward to your breaking research on #CARTtherapy. Would you like to feature your work on an international stage? Make sure to save the date for late-breaking abstract submission for #CART25, which will open January 1-12. Learn more: https://lnkd.in/dnvdsAm5

🚨Save the date!🚨 Join us for the ASH 2024 myeloma and AL amyloidosis highlights webinar on 18 December 2024, 17:00–18:00 CET. The session will be led by Dr. Charlotte Pawlyn, Haematologist and Clinician Scientist at the Institute of Cancer Research and The Royal Marsden Hospital. Click on the link to learn more and register!

🚨 Why does it take longer for new #medicines to reach #patients in the Netherlands? Carin Uyl-de Groot explains the challenges behind drug authorisation and reimbursement—and how the Netherlands often lags behind neighboring countries like Germany. Through the ASCERTAIN project, solutions like faster collective value assessments and streamlined negotiations are being explored to bring medicines to patients sooner. Want to learn more about this vital topic? 📖 Read the article here #ASCERTAIN #HealthcareAccess #InnovationInHealth #Pharmaceuticals

Fantastic visit at ISPOR, Barcelona. Poster presentation with: Benjamin Geisler Pia Henkel Yansi Wu and Leonie van Bemmelen It was a amazing possibility to present our ongoing work within ASCERTAIN and catch up with our collaborators from Erasmus School of Health Policy & Management (ESHPM), Oslo Economics, CONNECT, Magnus Bangum , Fredrik Holmboe, Carin Uyl-de Groot Thank you for all the great discussions! We look forward to seeing you again next year! Avdeling for helseledelse og helseøkonomi, Universitetet i Oslo (UiO) Det medisinske fakultet UiO Kine Pedersen Eline Aas Emily Burger